JonesResearch raised the firm’s price target on Femasys to $7 from $5 and keeps a Buy rating on the shares after the company received FDA 510(k) clearance for its lead asset FemaSeed, an intratubal insemination device. The analyst expects the device’s market to further expand with the Q1 of 2024 pivotal topline readout in male factor infertility. The firm now expects FemaSeed to launch nearly a full year ahead of schedule “given the swift regulatory decision.” It projects $290M in peak unadjusted sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FEMY:
- Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
- Femasys gets FDA clearance to market FemaSeed
- Femasys announces first-patient-in for clinical trial of FemBloc
- Femasys Inc. Obtains Medical Device Establishment License from Health Canada
- Femasys obtains MDEL from Health Canada